Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!
Site-specific glycosylation of Cetuximab is characterized in this service using multiple fractionation methods and capillary electrophoresis coupled to mass spectrometry (CE-MS) based glycomics. IdeS digested Cetuximab with subsequent reduction is fractionated using reversed-phase chromatography resulting in 3 fragments; Fd, Lc and Fc/2. Glycan release of the different fragments is performed in 18O enriched water providing the possible quantification of site occupancy.